

IN THE CLAIMS

1. (Currently Amended) A method of treating a mammal~~an individual~~ in need of treatment for a vascular permeability disorder, comprising administering to the mammal~~individual~~ in need of treatment for a vascular permeability disorder a therapeutically effective amount of a vascular endothelial sphingosine-1-phosphate receptor agonist, wherein the vascular endothelial sphingosine-1-phosphate receptor agonist is 2-amino-2-[2-(4-octaphenyl)ethyl]propane-1,3 diol, or 2-amino-2-methyl-4-[4-heptoxy-phenyl]butane-1-ol,

wherein the vascular permeability disorder is endothelial injury, thrombocytopenia, ischemic cardiovascular disease, ischemic peripheral vascular disease, a peripheral vascular disorder associated with diabetes, Dengue hemorrhagic fever, acute respiratory distress syndrome, vascular leak syndrome, or a combination comprising one or more of the foregoing disorders.

2-21. (Cancelled).

22. (Currently Amended) A method of treating a mammal~~an individual~~ in need of treatment for acute~~adult (acute)~~ respiratory distress syndrome, comprising administering to the mammal~~individual~~ in need of treatment for acute respiratory distress syndrome~~a vascular permeability disorder~~ a therapeutically effective amount of a vascular endothelial sphingosine-1-phosphate receptor agonist, wherein the vascular endothelial sphingosine-1-phosphate receptor agonist is 2-amino-2-[2-(4-octaphenyl)ethyl]propane-1,3 diol, or 2-amino-2-methyl-4-[4-heptoxy-phenyl]butane-1-ol.